RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.

GlobeNewsWire • 11 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX).   Such investors are advised to contact Danielle Peyton at  [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire • 5 hours ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX

NEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

PRNewsWire • 13 hours ago

RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp • 4 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.

Newsfile Corp • 38 minutes ago

Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc. (RGNX)

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit.

GlobeNewsWire • Feb 23, 2026

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2026.

PRNewsWire • Feb 23, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026.

GlobeNewsWire • Feb 23, 2026

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  REGENXBIO Inc. ("Regenxbio " or "the Company") (NASDAQ: RGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

PRNewsWire • Feb 23, 2026

ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.

Newsfile Corp • Feb 23, 2026